证券代码：688253 证券简称：英诺特 公告编号：2026-006 北京英诺特生物技术股份有限公司关于公司近期获 得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述产品的实际销售受到市场需求、市场竞争以及公司市场推广效果等多种 因素影响，利润贡献具有不确定性，尚无法预测上述产品对公司未来经营业绩的 影响。敬请广大投资者谨慎投资、注意投资风险。 特此公告。 北京英诺特生物技术股份有限公司董事会 2026 年 3 月 6 日 | 北京英诺特生物技 | 抗原联合检测试剂盒 | 国械注准 | | | | --- | --- | --- | --- | --- | | 术股份有限公司 | （乳胶层析法） | 20263400444 | | | | 获批主体 | 产品名称 偏肺病毒、副流感病毒 | 注册证号（备 案号） | 发证日期 2026/3/3 | 有效期至 2031/3/2 | 上述产品预期用途为用于体外定性检测口咽拭子样本中的偏肺病毒抗原、副 流感病毒抗原。 二、对公司的影响 上述资质的取得，拓 ...

Core Viewpoint - Innotech (688253) reported a decline in both revenue and net profit for the year 2025, while also announcing progress in new business and product developments [1] Business Performance - Innotech achieved an operating revenue of 422 million yuan in 2025, a year-on-year decrease of 32.08% - The net profit attributable to shareholders was 146 million yuan, down 40.84% year-on-year - The fluctuations in performance were primarily influenced by policy adjustments in the in vitro diagnostics industry, intensified competition in the respiratory testing sector, and a weaker flu season compared to the previous year [2] Business Progress - The company disclosed that its first single-molecule detection instrument and reagents for neurological testing have obtained product registration certificates - New registrations were also achieved in the international market, including EU IVDR and US FDA certifications - Collaborations with platforms like JD.com and Meituan are enhancing the brand building for home testing, which is expected to be a focal point for future business expansion [3] Company Status - From November 18 to December 1, 2025, Innotech conducted a shareholder reward activity, providing prizes to stockholders, reflecting the company's efforts to maintain shareholder relations [4]

Core Viewpoint - Innotech reported a significant decline in revenue and net profit for the fiscal year 2025, attributed to lower flu-like cases compared to 2024, but the company continues to invest in R&D and market expansion, particularly in international markets and new business ventures [1] Financial Performance - The total revenue for 2025 was 422 million yuan, representing a year-on-year decrease of 32.08% [1] - The net profit attributable to the parent company was 146 million yuan, down 40.84% year-on-year [1] Market and Product Development - The company faced challenges due to a decrease in flu-like cases, which significantly impacted revenue [1] - Despite these challenges, Innotech maintained high levels of investment in R&D and marketing, especially in international markets and new business areas [1] - In 2025, the company received approval for over ten new product registrations and collaborated with online platforms such as JD.com and Meituan to enhance brand recognition, laying a foundation for growth in 2026 [1]

Group 1: Major Announcements - Unisplendour plans to raise no more than 5.57 billion yuan through a private placement to acquire a 6.98% stake in New H3C and for other projects [2] - Zhongwei Semiconductor intends to establish an IPM production line project in Ziyang, Sichuan, using 1.21 billion yuan of leftover IPO funds [2] - Kaiying Network has signed a settlement agreement with Legend IP, which is expected to positively impact the company's profit by approximately 200 million yuan [2] Group 2: Project Developments - Blue Ocean Huaten plans to invest 8 million yuan in Wanren Technology to support its daily operations and AI project development [4] - Yuedian Power A has successfully put into operation the expansion project of the Huizhou Power Plant, which includes two 1000MW units [7] - Longmag Technology intends to raise up to 760 million yuan for its second phase project in Vietnam and chip inductor manufacturing [8] Group 3: Financial Performance - Top Group expects a net profit of 2.6 billion to 2.9 billion yuan for 2025, a decrease of 3.35% to 13.35% year-on-year due to rising raw material costs and increased market competition [20] - Jingchen Technology reported a net profit of 871 million yuan for 2025, a 6% increase year-on-year, with record high sales of over 174 million chips [21] - Guodian Xintong's net profit for 2025 is projected at 678 million yuan, a decline of 16.91% year-on-year, primarily due to increased credit impairment losses and tax expenses [22] Group 4: Shareholder Actions - Jieshun Technology's actual controller plans to reduce holdings by up to 2.8% of the company's shares [27] - Lihexing's controlling shareholder and concerted actors plan to collectively reduce their holdings by up to 1% [27] - Kory Technology's shareholders plan to reduce their holdings by a total of up to 3.13% [29] Group 5: Stock Buybacks - Quzhou Dongfeng plans to repurchase shares worth between 50 million and 100 million yuan, with a maximum price of 6.48 yuan per share [30]

Core Viewpoint - In the 2025 performance report, Innotec (688253) experienced significant declines in both revenue and net profit, attributed to industry policy impacts and intensified competition in its main business areas [1] Group 1: Financial Performance - Innotec reported a revenue of 422 million yuan for 2025, representing a year-on-year decrease of 32.08% [1] - The company achieved a net profit attributable to shareholders of 146 million yuan, down 40.84% year-on-year [1] Group 2: Industry Context - The in vitro diagnostic industry faced challenges due to regulatory policies related to medical insurance and taxation [1] - Increased competition in the specific testing fields of respiratory and digestive pathogens further pressured the company's performance in 2025 [1]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved a revenue of 422 million yuan, representing a year-on-year decrease of 32.08% [1] - The net profit attributable to shareholders was 146 million yuan, reflecting a year-on-year decline of 40.84% [1] - The basic earnings per share stood at 1.07 yuan [1]

Financial Performance - Total revenue for 2025 was CNY 42,203.03 million, a decrease of 32.08% compared to the previous year[2] - Net profit attributable to shareholders was CNY 14,604.47 million, down 40.84% year-on-year[2] - Basic earnings per share decreased by 40.88% to CNY 1.07[2] - The return on equity decreased by 5.54 percentage points to 7.20%[2] Assets and Investments - The company's total assets increased by 2.87% to CNY 227,605.75 million at the end of the reporting period[5] - The company increased its workforce and strategic investments, leading to higher human resource costs and R&D expenditures[7] Market and Product Development - The decline in performance was attributed to intensified industry competition and regulatory impacts on the in vitro diagnostics sector[6] - The company obtained over ten new product registrations domestically and internationally during 2025[7] - New business initiatives included entering the home testing market and developing neurological system testing products[7] - The company established brand recognition in the home testing sector through partnerships with online platforms like JD.com and Meituan[8]

Core Viewpoint - In 2025, the company Innotec (688253.SH) reported a significant decline in both revenue and net profit, primarily due to regulatory impacts and increased competition in the in vitro diagnostics industry [1] Financial Performance - The company achieved total operating revenue of 422 million yuan, representing a year-on-year decrease of 32.08% [1] - The net profit attributable to the parent company was 146 million yuan, reflecting a year-on-year decline of 40.84% [1] Industry Context - The in vitro diagnostics industry faced challenges from healthcare regulatory policies and tax policies, which negatively impacted the company's performance in 2025 [1] - Increased competition in specific testing areas, such as respiratory and digestive pathogens, further pressured the company's overall performance [1]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the fiscal year 2025, primarily due to industry challenges and increased costs [1] Financial Performance - The total operating revenue for 2025 was 422.03 million yuan, representing a year-on-year decrease of 32.08% [1] - The net profit attributable to the parent company was 146.04 million yuan, down 40.84% compared to the previous year [1] Industry Challenges - The decline in performance is attributed to the impact of policies on the in vitro diagnostic industry, intensified competition in specific testing areas, and a less favorable pathogen prevalence compared to 2024 [1] Cost Factors - Increased human resources costs, research and development expenditures, and marketing investments contributed to the larger decline in profit metrics [1] Future Outlook - Despite the current challenges, the company has made progress in research and marketing, laying a foundation for development in 2026 [1]

证券代码：688253 证券简称：英诺特 公告编号：2026-004 二、对公司的影响 上述资质的取得，拓宽了公司产品的种类，进一步提高了公司的市场拓展能 力及核心竞争力。 三、风险提示 上述产品的实际销售受到市场需求、市场竞争以及公司市场推广效果等多种 因素影响，利润贡献具有不确定性，尚无法预测上述产品对公司未来经营业绩的 影响。敬请广大投资者谨慎投资、注意投资风险。 北京英诺特生物技术股份有限公司关于公司近期获 得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）近期新取得产品资 质 1 项，具体情况如下表所示： | 北京英诺特生物技 | | 京械注准 | 2026/2/5 | | | --- | --- | --- | --- | --- | | 术股份有限公司 | （GFAP）测定试剂盒 | 20262400042 | | | | 获批主体 | 产品名称 胶质纤维酸性蛋白 （单分子免疫荧光法） | 注册证号（备 ...